![]() | |
![]() | |
Names | |
---|---|
IUPAC name
2′-Chloro-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methylpiperidin-4-yl]flavone
| |
Systematic IUPAC name
2-(2-Chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methylpiperidin-4-yl]-4H-1-benzopyran-4-one | |
Other names
Flavopiridol, HMR 1275, L-868275
| |
Identifiers | |
3D model (
JSmol)
|
|
ChEBI | |
ChEMBL | |
ChemSpider | |
DrugBank | |
KEGG | |
MeSH | Flavopiridol |
PubChem
CID
|
|
UNII | |
CompTox Dashboard (
EPA)
|
|
| |
| |
Properties | |
C21H20ClNO5 | |
Molar mass | 401.8402 |
Except where otherwise noted, data are given for materials in their
standard state (at 25 °C [77 °F], 100 kPa).
|
Alvocidib ( INN; also known as flavopiridol) is a flavonoid alkaloid CDK9 kinase inhibitor under clinical development by Tolero Pharmaceuticals for the treatment of acute myeloid leukemia. It has been studied also for the treatment of arthritis [1] and atherosclerotic plaque formation. [2] The target of alvocidib is the positive transcription elongation factor P-TEFb. [3] [4] Treatment of cells with alvocidib leads to inhibition of P-TEFb and the loss of mRNA production. [5] [6]
The compound is a synthetic analog of natural product rohitukine which was initially extracted from Aphanamixis polystachya (formerly Amoora rohituka, hence the name) and later from Dysoxylum binectariferum. [7] [8]
The FDA has granted orphan drug designation to alvocidib for the treatment of patients with acute myeloid leukemia. [9]
![]() | |
![]() | |
Names | |
---|---|
IUPAC name
2′-Chloro-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methylpiperidin-4-yl]flavone
| |
Systematic IUPAC name
2-(2-Chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methylpiperidin-4-yl]-4H-1-benzopyran-4-one | |
Other names
Flavopiridol, HMR 1275, L-868275
| |
Identifiers | |
3D model (
JSmol)
|
|
ChEBI | |
ChEMBL | |
ChemSpider | |
DrugBank | |
KEGG | |
MeSH | Flavopiridol |
PubChem
CID
|
|
UNII | |
CompTox Dashboard (
EPA)
|
|
| |
| |
Properties | |
C21H20ClNO5 | |
Molar mass | 401.8402 |
Except where otherwise noted, data are given for materials in their
standard state (at 25 °C [77 °F], 100 kPa).
|
Alvocidib ( INN; also known as flavopiridol) is a flavonoid alkaloid CDK9 kinase inhibitor under clinical development by Tolero Pharmaceuticals for the treatment of acute myeloid leukemia. It has been studied also for the treatment of arthritis [1] and atherosclerotic plaque formation. [2] The target of alvocidib is the positive transcription elongation factor P-TEFb. [3] [4] Treatment of cells with alvocidib leads to inhibition of P-TEFb and the loss of mRNA production. [5] [6]
The compound is a synthetic analog of natural product rohitukine which was initially extracted from Aphanamixis polystachya (formerly Amoora rohituka, hence the name) and later from Dysoxylum binectariferum. [7] [8]
The FDA has granted orphan drug designation to alvocidib for the treatment of patients with acute myeloid leukemia. [9]